Matt Gline, Roivant CEO (courtesy Roivant)
October 23, 2023 10:35 AM EDT
Deals
Pharma

Roivant CEO urges pa­tience on fu­ture af­ter $7B+ sale to Roche

Max Gelman

Senior Editor

Now that Roivant has end­ed months of ru­mors by sign­ing a deal to sell its an­ti-TL1A in­hibitor to Roche for $7.1 bil­lion up­front, every­one wants …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times